Balana C, et al. - Researchers retrospectively examined unresected glioblastoma patients receiving neoadjuvant therapy followed by standard treatment (NA group) vs patients receiving standard treatment without neoadjuvant therapy (NoNA group) to determine the potential effect on overall survival (OS) of delaying radiotherapy to administer neoadjuvant therapy in unresected glioblastoma patients. The optimal cut-off point for waiting time to radiotherapy was identified by the MaxStat package of R. Although the start of radiotherapy in unresected patients receiving neoadjuvant treatment was delayed, no inferior OS was reported in these patients vs a similar group of patients with no delay in starting radiotherapy.